Health Secretary Robert F. Kennedy Jr. has appointed nine new advisors to an FDA panel, most of whom have financial ties to peptide clinics, to push for broader access to unproven injectable drugs. This move directly contradicts FDA scientists' findings that these peptides lack sufficient evidence of safety and efficacy.
Background
The FDA typically relies on independent scientific advisory committees to evaluate drug safety and efficacy before making regulatory decisions. Recent political appointments have raised concerns about potential conflicts of interest in drug approval processes.
- Source
- Ars Technica
- Published
- Jul 1, 2026 at 02:25 AM
- Score
- 7.0 / 10